Biohaven Faces Major Clinical & Regulatory Setbacks for Key Pipeline Assets

summarizeSummary

Biohaven Ltd.'s annual report reveals significant late-stage clinical trial failures for Opakalim in MDD and bipolar disorder, a Complete Response Letter from the FDA for troriluzole in SCA, and the termination of a key oncology collaboration.

check_boxKey Events

• Troriluzole NDA Rejected by FDA, EMA Application Withdrawn

  Biohaven received a Complete Response Letter (CRL) from the FDA in November 2025 for its New Drug Application (NDA) for troriluzole in Spinocerebellar Ataxia (SCA). The FDA recommended further discussion on the evidence needed for a future NDA. Additionally, the EMA Marketing Authorization Application (MAA) for troriluzole in SCA was withdrawn in March 2025 due to insufficient data for 'new active substance' status, despite positive topline results from a 3-year real-world evidence study.

• Opakalim Fails in MDD and Bipolar Disorder Trials

  Phase 2 trials for Opakalim in Major Depressive Disorder (MDD) (December 2025) and Phase 2/3 trials for acute bipolar disorder (March 2025) both failed to meet their primary endpoints. Consequently, Biohaven plans no additional psychiatric clinical trials for Opakalim, reallocating resources to higher-priority development activities.

• Merus Collaboration for ADCs Terminated

  The research collaboration and license agreement with Merus N.V. to co-develop three novel dual-targeting antibody-drug conjugates (ADCs) was terminated in January 2026, following the acquisition of Merus by Genmab A/S.

• Strategic Pipeline Reprioritization

  In Q4 2025, Biohaven initiated strategic portfolio and cost-optimization measures to prioritize three key late-stage clinical programs: Kv7 ion channel modulation for epilepsy, MoDE/TRAP extracellular protein degradation for immunological diseases, and myostatin-activin pathway targeting for neuromuscular and metabolic diseases, including obesity.

auto_awesomeAnalysis

Biohaven Ltd.'s annual report highlights a challenging period, marked by multiple late-stage clinical and regulatory setbacks for key pipeline assets. The FDA's Complete Response Letter for troriluzole in Spinocerebellar Ataxia (SCA) and the withdrawal of its EMA application represent significant hurdles for a program that was a focus of recent debt financing. The failures of Opakalim in both Major Depressive Disorder (MDD) and bipolar disorder trials, leading to the cessation of psychiatric development, further narrow the company's near-term growth prospects in neuroscience. The termination of the Merus ADC collaboration also removes a potential oncology asset. While the company has strategically reprioritized its pipeline and secured additional capital, these setbacks underscore the high-risk nature of drug development and will likely impact investor confidence and future valuation. Investors should closely monitor progress in the remaining key programs and the outcome of the ongoing shareholder lawsuit.